Filing Details

Accession Number:
0001235802-22-000100
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-17 17:10:00
Reporting Period:
2022-08-15
Accepted Time:
2022-08-17 17:10:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1453593 Xtant Medical Holdings Inc. XTNT Biological Products, (No Disgnostic Substances) (2836) 205313323
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1902610 C Scott Neils 664 Cruiser Lane
Belgrade MT 59714
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.000001 Par Value Acquisiton 2022-08-15 251,895 $0.00 419,003 No 4 A Direct
Common Stock, $0.000001 Par Value Disposition 2022-08-16 5,100 $0.48 413,903 No 4 S Direct
Common Stock, $0.000001 Par Value Disposition 2022-08-17 1,270 $0.48 412,633 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. These shares will vest and be issued with respect to 62,974 shares on each of August 15, 2023, August 15, 2024, and August 15, 2025 and with respect to 62,973 shares on August 15, 2026 pursuant to a restricted stock unit award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan, conditioned upon the Reporting Person remaining an employee of Xtant through the vesting date
  2. Includes 58,594 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 340,878 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.
  3. These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47161 to $0.517084, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47 to $0.4953, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.